Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

E-6201

Generic Name: E-6201

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₇NO_₆

CAS Number: 603987-35-5

Unique Ingredient Identifier: CZP9GB25HO

Overview

E6201 has been investigated for the treatment of Chronic Plaque Psoriasis.

Background

E6201 has been investigated for the treatment of Chronic Plaque Psoriasis.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Phase 1

Recruiting

Posted: 2024/02/02

Sponsor:JS InnoPharm, LLC

ID:NCT06239623

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1

Suspended

Posted: 2020/06/05

Sponsor:JS InnoPharm, LLC

ID:NCT04418167

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Phase 1

Terminated

Posted: 2017/11/06

Sponsor:Spirita Oncology, LL...

ID:NCT03332589

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Phase 1

Terminated

Posted: 2015/04/16

Sponsor:Spirita Oncology, LL...

ID:NCT02418000

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Posted: 2008/11/20

Sponsor:Eisai Inc.

ID:NCT00794781

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy